NOVOS has raised $9.0M in total across 2 funding rounds.
NOVOS's investors include Lorie&co, MizMaa Ventures, Arkitekt Ventures, Arrive, Beckett Layne Ventures, BITKRAFT Ventures, Curie.Bio, E1 Ventures, Griffin Gaming Partners, Insight Partners, Khosla Ventures, Koch Fund.
NOVOS is a data- and research-driven longevity company founded in 2018, headquartered in New York City, that develops science-backed nutraceutical supplements targeting the root causes of aging to promote healthier aging and extend human lifespan.[3][5][6] It offers four powerful formulas with over 20 innovative ingredients, supported by 950+ studies, including NOVOS Core, which has shown an 18% lifespan increase in aged mice and up to 77% DNA protection in human skin cells from UV and chemo damage.[5][6] Serving consumers seeking anti-aging solutions, NOVOS simplifies wellness routines to enhance energy, cognition, skin health, and vitality, with over 10 million servings taken and users reporting 1.6 months less epigenetic age annually based on thousands of tests.[6] The company has raised under $5 million in funding and boasts a 4.7/5 user rating.[3][6]
NOVOS was founded in 2018 by longevity expert Chris Mirabile, emerging from rigorous four-year testing and formulation to launch its patent-pending supplement line in a beta and introductory phase before full debut.[3][6] The idea stemmed from breakthroughs in aging science, positioning NOVOS as the pioneer in consumer longevity by creating the first formula addressing 12 fundamental causes of aging, backed by deep biotech expertise including genomics, personalized medicine, and gene therapy.[3][5] Early traction included successful beta testing, high user satisfaction, and scientific validation like epigenetic age reductions via the DunedinPACE algorithm from Duke and Columbia researchers, humanizing its mission through real-world longevity impacts.[5][6]
NOVOS rides the explosive longevity biotech trend, fueled by advances in epigenetics, AI-driven aging clocks like DunedinPACE, and consumer demand for preventive health amid rising life expectancies and chronic disease burdens.[5][6] Timing is ideal post-2018 launch, aligning with post-pandemic wellness booms and $5M+ funding in anti-aging, where market forces like genomic sequencing democratization and personalized medicine favor scalable nutraceuticals over expensive therapies.[3][5] It influences the ecosystem by democratizing elite longevity science for consumers, bridging academic research (e.g., mouse/human cell studies) to mainstream use, and competing with NAD+ supplements while pioneering multi-cause aging interventions.[6]
NOVOS is poised to dominate consumer longevity with expanding evidence (e.g., more epigenetic data, human trials) and formula iterations amid trends like AI-optimized nutraceuticals and integrated wearables for real-time aging tracking.[5][6] Regulatory tailwinds for supplements and partnerships with biotech could scale it beyond <$5M revenue, potentially evolving into a full-stack wellness platform influencing how millions "live younger longer."[3][6] As aging science accelerates, NOVOS's root-cause approach positions it to redefine healthy aging, tying back to its core promise of evidence-backed vitality for all.
NOVOS has raised $9.0M across 2 funding rounds. Most recently, it raised $6.0M Seed in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2022 | $6.0M Seed | Lorie&co, MizMaa Ventures | |
| Sep 1, 2021 | $3.0M Seed | Arkitekt Ventures, Arrive, Beckett Layne Ventures, BITKRAFT Ventures, Curie.Bio, E1 Ventures, Griffin Gaming Partners, Insight Partners, Khosla Ventures, Koch Fund, Lakeside Capital, Lightspeed Venture Partners, Operator Partners, Partners Resolute, Predictive VC, Henry Fertik, Assaf Wand, Kevin Colas, Oded Hermoni, Rashaun Williams |
